Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Induced pluripotent stem cells (iPSCs) possess the unique capability to differentiate into various cell types, making them an ideal starting point for generating NK cells. The innovative approach leverages the versatility and availability of iPSCs to induce NK cells, making it a promising "off-the-shelf" option for cancer treatment. As an industry leader in the cell therapy field, Creative Biolabs offers a range of allogeneic cell therapy development services tailored to the specific needs of our clients. Our CAR-iNK services involve modifying iPSC-derived NK cells with a CAR construct, ensuring highly efficient and targeted immunotherapeutic solutions.
Fig.1 Genetic modifications to improve the functions of iNK cells.1
To enhance the anti-tumor efficiency of iNK cells, Creative Biolabs utilizes advanced genetic engineering techniques to modify iPSCs. These modifications include knocking in a CAR gene into the iPSCs. CARs are designed to recognize and bind to antigens present on the surface of cancer cells, thus directing the NK cells toward their targets with high specificity. Moreover, Creative Biolabs is dedicated to addressing one of the immune suppression challenges in cancer immunotherapy. Our experts are able to edit multiple genes within the iPSCs to knock out immunosuppressive elements by CRISPR/Cas9. These methods eradicate the mechanisms that tumors often use to evade immune detection and destruction and ensure a sustained and potent anti-tumoral response.
Creative Biolabs has developed proprietary technology to induce NK cells from iPSCs effectively. Our feeder-free differentiation platform ensures a highly efficient and reproducible process for generating iNK cells. Unlike traditional methods that require feeder layers, which can introduce variability and contaminants, our feeder-free system offers a cleaner, more consistent and controlled way to produce iNK cells, ultimately resulting in a purer product ready for further applications.
Creative Biolabs utilizes several cutting-edge technologies in their CAR-iNK cell development services:
This technology ensures the reliable and scalable production of NK cells from iPSCs.
By designing iPSCs to express CARs that target specific cancer antigens, Creative Biolabs enhances the targeting precision and cytotoxicity of the resultant iNK cells.
The use of CRISPR/Cas9 to knock out immunosuppressive genes bolsters the resilience and effectiveness of iNK cells in combating tumors.
With a commitment to innovation and quality, Creative Biolabs stands distinguished in providing CAR-iNK cell development services. By integrating proprietary methods for iNK cell induction with CRISPR/Cas9-mediated gene editing, we are pioneering the next generation of allogeneic cancer therapies. For further discussions or to initiate a collaboration, please contact Creative Biolabs today. Our experts are ready to guide you through every step of your CAR-iNK cell development journey.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
